Patents by Inventor Tongzheng LIU

Tongzheng LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEATR1 as a marker for chemoresistance
    Patent number: 11371099
    Abstract: The present invention relates to methods of using HEATR1 expression levels for guiding chemotherapy treatment of pancreatic cancer. In particular, measuring lower HEATR1 expression in pancreatic cancer is associated with resistance to the use of certain chemotherapy treatments such that by changing the treatment a better prognosis may be obtained for the patient. Further, lower HEATR1 expression is related to a poorer long-term prognosis of pancreatic cancer patients thus measuring an increase or maintenance/decrease during treatment may be useful for predicting treatment response.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: June 28, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Zhenkun Lou, Tongzheng Liu
  • Method of treating cancer metastasis by CDK 4/6 inhibitors
    Patent number: 10690673
    Abstract: This document provides materials and methods for treating cancer metastases. For example, materials and methods for using a CDK 4/6 inhibitor and/or a CDK1 inhibitor to prevent cancer cell metastasis, prevent further cancer cell metastasis, reduce the number of metastatic cancer cells, and/or reduce the risk of cancer cell metastasis within a mammal (e.g., a human) are provided.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 23, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Zhenkun Lou, Tongzheng Liu
  • TREATING CANCER METASTASIS
    Publication number: 20190120844
    Abstract: This document provides materials and methods for treating cancer metastases. For example, materials and methods for using a CDK 4/6 inhibitor and/or a CDK1 inhibitor to prevent cancer cell metastasis, prevent further cancer cell metastasis, reduce the number of metastatic cancer cells, and/or reduce the risk of cancer cell metastasis within a mammal (e.g., a human) are provided.
    Type: Application
    Filed: March 28, 2017
    Publication date: April 25, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Zhenkun Lou, Tongzheng Liu
  • HEATR1 AS A MARKER FOR CHEMORESISTANCE
    Publication number: 20180346991
    Abstract: The present invention relates to methods of using HEATR1 expression levels for guiding chemotherapy treatment of pancreatic cancer. In particular, measuring lower HEATR1 expression in pancreatic cancer is associated with resistance to the use of certain chemotherapy treatments such that by changing the treatment a better prognosis may be obtained for the patient. Further, lower HEATR1 expression is related to a poorer long-term prognosis of pancreatic cancer patients thus measuring an increase or maintenance/decrease during treatment may be useful for predicting treatment response.
    Type: Application
    Filed: November 16, 2016
    Publication date: December 6, 2018
    Inventors: Tongzheng LIU, Zhenkun LOU